Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at ...
Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is approved, strengthening its Sanofi partnership. Novavax, Inc. (NASDAQ:NVAX ...
TipRanks on MSN
Novavax Enters Lease Agreement with AstraZeneca
The latest announcement is out from Novavax ( (NVAX) ).
NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...
GAITHERSBURG, Md., Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid ™ 2025-2026 Formula for the ...
SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologic s, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc.
Novavax (NVAX) stock is in focus as the company assign its Gaithersburg facility to AstraZeneca (AZN) in a deal worth nearly ...
GAITHERSBURG, Md., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback